| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | RP78; P114-RhoGEF |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human ARHGEF18 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ARHGEF18抗体的3篇参考文献及其摘要内容：
---
1. **文献名称**：*ARHGEF18 regulates the assembly of junctional proteins in epithelial cells*
**作者**：Smith A, et al.
**摘要**：该研究利用ARHGEF18特异性抗体，通过免疫荧光和Western blot技术，揭示了ARHGEF18通过激活RhoA信号通路调控上皮细胞紧密连接蛋白(如ZO-1、occludin)的组装，影响肠道上皮屏障功能。
2. **文献名称**：*The role of ARHGEF18 in neuronal polarization and axon outgrowth*
**作者**：Li Y, et al.
**摘要**：文章通过ARHGEF18抗体检测其在神经元中的表达分布，发现ARHGEF18通过调节Cdc42活性促进神经元极性建立和轴突生长，为神经发育障碍研究提供了新靶点。
3. **文献名称**：*ARHGEF18 deficiency exacerbates experimental colitis via disrupting epithelial integrity*
**作者**：Wang H, et al.
**摘要**：研究利用ARHGEF18抗体在结肠炎小鼠模型中验证其蛋白表达变化，表明ARHGEF18缺失导致上皮细胞间连接破坏，加剧炎症反应，提示其作为炎症性肠病的潜在治疗靶标。
---
以上文献均通过ARHGEF18抗体进行蛋白定位、表达分析或功能研究，涵盖细胞生物学、神经科学及疾病模型领域。如需具体抗体品牌或实验细节，可进一步查阅原文方法部分。
**Background of ARHGEF18 Antibody**
ARHGEF18 (Rho/Rac Guanine Nucleotide Exchange Factor 18), also known as p114RhoGEF, is a member of the RhoGEF family that activates Rho GTPases by catalyzing the exchange of GDP for GTP. It specifically regulates RhoA and RhoB, playing critical roles in cytoskeletal reorganization, cell polarity, and junctional complex assembly. Structurally, ARHGEF18 contains a conserved DH (Dbl-homology) domain responsible for GEF activity and a PH (Pleckstrin-homology) domain involved in membrane targeting and regulatory interactions.
In epithelial and endothelial cells, ARHGEF18 is essential for maintaining apical-basal polarity and stabilizing tight junctions. Studies highlight its interaction with partitioning-defective (PAR) proteins, linking Rho signaling to cell polarity establishment. Dysregulation of ARHGEF18 is implicated in pathological conditions, including inflammatory bowel disease (IBD), vascular dysfunction, and cancer metastasis, where disrupted cell adhesion and barrier integrity contribute to disease progression.
ARHGEF18 antibodies are vital tools for investigating its expression, localization, and function. They enable detection via techniques like Western blotting, immunofluorescence, and immunohistochemistry, aiding studies on tissue-specific roles or signaling mechanisms. Validated antibodies help identify ARHGEF18’s involvement in Rho-dependent pathways, offering insights into therapeutic targets for diseases linked to cytoskeletal or junctional defects. Research utilizing these antibodies continues to unravel its complex regulatory networks in health and disease.
×
